PROCEPT BioRobotics Corporation Operating Expenses
PROCEPT BioRobotics Corporation (PRCT) reported Operating Expenses of $89.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- PROCEPT BioRobotics Corporation operating expenses for the quarter ending 2026-06-30 was $89.77M, a 21.42% increase year-over-year.
- PROCEPT BioRobotics Corporation operating expenses for the quarter ending 2026-03-31 was $86.55M, a 20.89% increase year-over-year.
- PROCEPT BioRobotics Corporation operating expenses for the quarter ending 2025-12-31 was $77.35M, a 22.04% increase year-over-year.
- PROCEPT BioRobotics Corporation operating expenses for the quarter ending 2025-09-30 was $77.20M, a 30.10% increase year-over-year.
- PROCEPT BioRobotics Corporation operating expenses for fiscal 2025 was $300.08M, a 28.40% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation operating expenses for fiscal 2024 was $233.71M, a 29.68% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation operating expenses for fiscal 2023 was $180.22M, a 52.98% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation operating expenses for fiscal 2022 was $117.81M, a 68.23% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.77M 10-Q · filed 2026-08-05 | $176.32M 10-Q · filed 2026-08-05 | $253.68M derived: sum of 3 quarters · filed 2026-08-05 | $330.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $86.55M 10-Q · filed 2026-04-30 | $163.91M derived: sum of 2 quarters · filed 2026-04-30 | $241.10M derived: sum of 3 quarters · filed 2026-04-30 | $315.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $77.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $154.55M derived: sum of 2 quarters · filed 2026-02-26 | $228.49M derived: sum of 3 quarters · filed 2026-08-05 | $300.08M 10-K · filed 2026-02-26 |
| 2025-09-30 | $77.20M 10-Q · filed 2025-11-05 | $151.13M derived: sum of 2 quarters · filed 2026-08-05 | $222.73M 10-Q · filed 2025-11-05 | $286.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $73.94M 10-Q · filed 2026-08-05 | $145.53M 10-Q · filed 2026-08-05 | $208.92M derived: sum of 3 quarters · filed 2026-08-05 | $268.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $71.60M 10-Q · filed 2026-04-30 | $134.98M derived: sum of 2 quarters · filed 2026-04-30 | $194.32M derived: sum of 3 quarters · filed 2026-04-30 | $252.63M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $63.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $122.72M derived: sum of 2 quarters · filed 2026-02-26 | $181.03M derived: sum of 3 quarters · filed 2026-02-26 | $233.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $59.34M 10-Q · filed 2025-11-05 | $117.65M derived: sum of 2 quarters · filed 2025-11-05 | $170.33M 10-Q · filed 2025-11-05 | $221.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $58.31M 10-Q · filed 2025-08-07 | $110.99M 10-Q · filed 2025-08-07 | $161.81M derived: sum of 3 quarters · filed 2026-02-26 | $206.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $52.68M 10-Q · filed 2025-05-02 | $103.50M derived: sum of 2 quarters · filed 2026-02-26 | $147.98M derived: sum of 3 quarters · filed 2026-02-26 | $192.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $50.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $95.30M derived: sum of 2 quarters · filed 2026-02-26 | $139.35M derived: sum of 3 quarters · filed 2026-02-26 | $180.22M 10-K · filed 2026-02-26 |
| 2023-09-30 | $44.48M 10-Q · filed 2024-10-28 | $88.54M derived: sum of 2 quarters · filed 2024-10-28 | $129.41M 10-Q · filed 2024-10-28 | $165.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $44.05M 10-Q · filed 2024-08-02 | $84.92M 10-Q · filed 2024-08-02 | $120.64M derived: sum of 3 quarters · filed 2025-02-27 | $152.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $40.87M 10-Q · filed 2024-05-02 | $76.58M derived: sum of 2 quarters · filed 2025-02-27 | $108.92M derived: sum of 3 quarters · filed 2025-02-27 | $135.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $35.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $68.05M derived: sum of 2 quarters · filed 2025-02-27 | $94.41M derived: sum of 3 quarters · filed 2025-02-27 | $117.81M 10-K · filed 2025-02-27 |
| 2022-09-30 | $32.34M 10-Q · filed 2023-11-02 | $58.70M derived: sum of 2 quarters · filed 2023-11-02 | $82.09M 10-Q · filed 2023-11-02 | $103.44M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $26.36M 10-Q · filed 2023-07-28 | $49.76M 10-Q · filed 2023-07-28 | $71.10M derived: sum of 3 quarters · filed 2024-02-28 | $88.14M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $23.40M 10-Q · filed 2023-05-04 | $44.74M derived: sum of 2 quarters · filed 2024-02-28 | $61.78M derived: sum of 3 quarters · filed 2024-02-28 | $78.56M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $21.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $38.38M derived: sum of 2 quarters · filed 2024-02-28 | $55.16M derived: sum of 3 quarters · filed 2024-02-28 | $70.03M 10-K · filed 2024-02-28 |
| 2021-09-30 | $17.04M 10-Q · filed 2022-11-04 | $33.81M derived: sum of 2 quarters · filed 2022-11-04 | $48.68M 10-Q · filed 2022-11-04 | $62.36M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $16.77M 10-Q · filed 2022-08-05 | $31.65M 10-Q · filed 2022-08-05 | $45.32M derived: sum of 3 quarters · filed 2022-08-05 | $56.27M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $14.87M 10-Q · filed 2022-05-06 | $28.55M derived: sum of 2 quarters · filed 2022-05-06 | $39.49M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $13.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $24.62M derived: sum of 2 quarters · filed 2022-03-22 | $46.55M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $10.95M 10-Q · filed 2021-11-05 | $32.87M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |